Bipolar disorder treatment for West Palm Beach — the diagnosis primary care misses.

RECO Integrated Psychiatry's Delray Beach office is 28 minutes south of Downtown WPB on I-95 — the nearest outpatient practice that treats bipolar disorder with lithium-level monitoring rigor. The evaluation uses MDQ, HCL-32, and structured mood charting rather than a symptom checklist, and every medication decision is anchored to a specific phase of illness. Telepsychiatry follow-up is available for El Cid, Flamingo Park, and Northwood Hills clients who prefer to avoid the second drive after diagnostic stability is achieved.

West Palm Beach sits 18 miles north of RECO Integrated Psychiatry’s Delray Beach office — 28 minutes down I-95 or Federal Highway outside rush hour. For residents of El Cid, Flamingo Park, Northwood Hills, SoSo, and Downtown WPB, the Delray campus is the nearest outpatient practice that treats bipolar disorder with the diagnostic rigor the condition requires. Misdiagnosis of bipolar depression as unipolar drives most treatment failures in this population, which is why the workup here starts with getting the diagnosis right.

Bipolar I, bipolar II, and bipolar spectrum: the diagnosis primary care misses

Bipolar I requires a lifetime manic episode — seven days or hospitalization, with elevated or irritable mood plus three or more DSM-5 B criteria (grandiosity, decreased need for sleep, pressured speech, flight of ideas, distractibility, goal-directed activity, risky behavior). Bipolar II requires at least one hypomanic episode of four or more days plus a major depressive episode, and by definition there has never been a manic episode. Bipolar spectrum — cyclothymia, other-specified bipolar, antidepressant-induced hypomania that resolves off the medication — captures clear cyclicity that does not meet full criteria.

The distinction changes the pharmacology. Bipolar I responds best to lithium or valproate paired with a second-generation antipsychotic through mania and into maintenance. Bipolar II depression has the strongest evidence for lamotrigine and quetiapine; lithium’s role is less straightforward in this subtype, and antidepressant monotherapy carries a documented switch and cycle-acceleration risk. Bipolar spectrum presentations require honest conversations about whether an antidepressant belongs at all, and if so, only under mood stabilizer cover.

The evaluation uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist (HCL-32), structured mood charting across the prior twelve months, and collateral history from a family member where the client consents. First-degree family history of bipolar disorder, early age at first depressive episode, postpartum onset, seasonality, atypical features, and prior antidepressant-induced activation all shift the pretest probability. Bipolar disorder treatment at RECO begins with getting the classification right — every downstream medication decision depends on it.

Lithium: the treatment we take seriously when others don’t

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychiatric medication with replicated evidence of an anti-suicide effect independent of its mood effect. It reduces relapse in both poles and works synergistically with antipsychotics in acute mania. Many clinicians avoid prescribing it because the monitoring feels burdensome; that reluctance steers patients who would benefit toward less effective alternatives.

The protocol builds monitoring in. Baseline workup includes TSH, creatinine and estimated GFR, calcium, CBC, urine specific gravity, pregnancy testing where relevant, and an ECG in patients over forty or with cardiac history. Maintenance target is 0.6–1.0 mEq/L drawn as a twelve-hour trough; acute mania is dosed toward 0.8–1.2 mEq/L. Levels are checked five days after any dose change, quarterly through the first year, then twice yearly at steady state alongside TSH and renal function.

Interactions matter: NSAIDs, ACE inhibitors, ARBs, and thiazide diuretics all raise lithium levels, and dehydration in a Palm Beach County summer can push a stable patient into toxicity. Clients are counseled explicitly on early toxicity signs — coarse tremor, ataxia, confusion, GI symptoms — and on when to hold a dose and call. For clients who tolerate lithium, the outcomes justify the monitoring burden by a wide margin.

Second-generation antipsychotics and where they fit

Every second-generation antipsychotic used in bipolar disorder has a specific FDA-approved indication. Quetiapine carries approvals across bipolar depression, acute mania, and maintenance, which makes it uniquely versatile. Lurasidone has strong bipolar depression evidence and a favorable metabolic profile, dosed with food. Aripiprazole is approved for acute mania and maintenance and is activating, which is useful in bipolar depression only sometimes. Olanzapine and olanzapine-fluoxetine cover bipolar depression and mania but carry the highest metabolic burden of the class. Risperidone and cariprazine treat acute mania, and cariprazine has emerging bipolar depression data.

Choice is driven by phase of illness, prior response history, and tolerability. Metabolic monitoring is not optional — baseline weight, waist circumference, blood pressure, fasting glucose or HbA1c, and lipid panel, then quarterly weight and BP with at least annual metabolic labs. AIMS is documented at baseline and every six months for tardive dyskinesia surveillance. Prolactin is checked on risperidone with symptoms, and QTc is considered on ziprasidone and higher-dose quetiapine.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest evidence for maintenance where depression is the predominant pole and is a first-line option in bipolar II depression. Titration is slow — 25 mg daily for two weeks, 50 mg for two weeks, 100 mg for one week, then 200 mg — because rapid titration increases the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. Any rash in the first eight weeks stops the drug pending evaluation. Concurrent valproate doubles lamotrigine levels and requires halved dosing; carbamazepine and estrogen-containing contraceptives lower levels and require adjustment.

Valproate is effective for acute mania and mixed states and remains a maintenance option, particularly in rapid-cycling presentations. Baseline includes LFTs, CBC with platelets, and pregnancy testing — valproate is a known teratogen with neural tube defect risk, and it is not prescribed to patients who can become pregnant without a documented contraception plan and a clear clinical rationale. Serum levels target 50–125 mcg/mL, with LFTs and platelets rechecked at three months and every six to twelve months thereafter. Carbamazepine is a reasonable second-line agent with autoinduction over the first four weeks, CBC and LFT monitoring, and HLA-B*1502 screening in patients of Asian ancestry.

What to expect at your first visit

The initial psychiatric evaluation is 75 to 90 minutes. It covers longitudinal mood history, a detailed medication trial history including specific reasons for discontinuation, substance use screening, family psychiatric history, medical comorbidities, current stressors, and safety assessment. PHQ-9 and GAD-7 are administered as baseline symptom measures alongside the MDQ or HCL-32; ASRS is added when adult ADHD is on the differential, and YBOCS when OCD-spectrum features are present.

A working diagnosis, a specific medication plan, any baseline labs (TSH, creatinine, LFTs, CBC, HbA1c and lipids where indicated), and a follow-up cadence are documented before the client leaves. Follow-up is typically weekly during titration or acute stabilization, biweekly during dose refinement, and monthly to quarterly at maintenance. Telepsychiatry is available for follow-up visits for West Palm Beach clients who prefer to avoid the drive after diagnostic stability is achieved.

Insurance and admissions from West Palm Beach

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans. Benefits are verified before the first appointment so the client knows their copay, deductible progress, and any prior authorization requirement up front. Cash-pay rates are published, and superbills are provided for out-of-network reimbursement where applicable. Most West Palm Beach clients drive in for the intake and any labs and then transition to a mix of in-person and telepsychiatry follow-up.

Serving residents of: El Cid, Flamingo Park, Northwood Hills, SoSo, Downtown WPB.